Isoxazolidines as RIPK1 inhibitors and uses thereof

Novel heterocyclic compounds targeting RIPK1 offer a more effective and specific approach to treating RIPK1-mediated diseases, addressing the limitations of existing treatments by reducing inflammation and cell death with improved therapeutic profiles.

CN119731170APending Publication Date: 2025-03-28GENZYME CORP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202380060140.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-19
Filing Date
2023-08-17
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Current treatments for diseases mediated by receptor-interacting protein kinase 1 (RIPK1) lack specificity and efficacy, leading to potential off-target effects and limited therapeutic options for conditions like chronic inflammation and cell death-related disorders.

Method used

Development of novel compounds, specifically heterocyclic compounds such as those with a 3-[(3S)-2-[1-(6-aminopyrimidin-4-yl)piperidin-4-yl]imidazolidine-3-yl]methanone structures, which act as selective RIPK1 inhibitors, offering improved therapeutic profiles for treating RIPK1-driven diseases.

Benefits of technology

These compounds effectively inhibit RIPK1, reducing inflammation and cell death, providing a potential therapeutic avenue for conditions like arthritis, multiple sclerosis, and Alzheimer's disease by targeting the underlying molecular mechanisms with enhanced specificity and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005273688570000021
    Figure BDA0005273688570000021
  • Figure BDA0005273688570000051
    Figure BDA0005273688570000051
  • Figure BDA0005273688570000291
    Figure BDA0005273688570000291
Patent Text Reader

Abstract

Disclosed herein are isoxazolidine compounds and their use as inhibitors of receptor interacting protein kinase 1, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Heterocyclic amides as kinase inhibitors

    WO2014125444A1

  • Heterocyclic amides as rip1 kinase inhibitors as medicaments

    WO2016027253A1

  • Heterocyclic amides as kinase inhibitors

    WO2016185423A1

  • Heterocyclic amides as kinase inhibitors

    WO2018092089A1

  • Heterocyclic amides as kinase inhibitors

    WO2019130230A1